patient_id stringlengths 20 22 | cancer_type stringclasses 1
value | histology stringclasses 2
values | stage_at_diagnosis stringclasses 2
values | molecular_profile dict | baseline_clinical dict | disease_burden_at_dx dict | treatment_course dict | survival_outcomes dict | longitudinal_labs listlengths 3 3 |
|---|---|---|---|---|---|---|---|---|---|
ANODE_SYNTH_2025_401 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 85,
"sex": "female",
"bmi": 20.9,
"smoking_pack_years": 40,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.6,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-12-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -45
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 6.9,
"censored": false
} | [
{
"date": "2022-11-23T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 5.7,
"platelets_k_uL": 398,
"creatinine_mg_dL": 0.75,
"alt_U_L": 44
},
{
"date": "2023-06-08T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 4,
"platelets_k_uL": 219,
"creatinine_mg_dL": 1.55,
"... |
ANODE_SYNTH_2025_402 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 68,
"sex": "male",
"bmi": 24.8,
"smoking_pack_years": 48,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.9,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-03-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -81
},
"pfs_months": 19.78
... | {
"overall_survival_months": 41.2,
"censored": true
} | [
{
"date": "2025-02-19T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 8.4,
"platelets_k_uL": 244,
"creatinine_mg_dL": 0.63,
"alt_U_L": 52
},
{
"date": "2025-09-04T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 4.2,
"platelets_k_uL": 272,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 57,
"sex": "female",
"bmi": 36.3,
"smoking_pack_years": 69,
"ecog_performance_status": 2,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"bone",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-02-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -19,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 19.65
... | {
"overall_survival_months": 24,
"censored": false
} | [
{
"date": "2021-12-23T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 7.3,
"platelets_k_uL": 312,
"creatinine_mg_dL": 0.94,
"alt_U_L": 50
},
{
"date": "2022-08-12T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 5.2,
"platelets_k_uL": 207,
"creatinine_mg_dL": 0.82,
... |
ANODE_SYNTH_2025_404 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 78,
"sex": "female",
"bmi": 33.8,
"smoking_pack_years": 57,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.5,
"metastatic_sites": [
"contralateral lung",
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-03-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 17.5,
"censored": true
} | [
{
"date": "2023-02-19T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 6.7,
"platelets_k_uL": 185,
"creatinine_mg_dL": 1.04,
"alt_U_L": 45
},
{
"date": "2023-09-26T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 6.8,
"platelets_k_uL": 355,
"creatinine_mg_dL": 1,
"a... |
ANODE_SYNTH_2025_405 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 62,
"sex": "male",
"bmi": 26.4,
"smoking_pack_years": 67,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"bone",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-03-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 18.4,
"censored": false
} | [
{
"date": "2023-02-20T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 6.5,
"platelets_k_uL": 403,
"creatinine_mg_dL": 0.94,
"alt_U_L": 68
},
{
"date": "2023-09-23T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 6.2,
"platelets_k_uL": 329,
"creatinine_mg_dL": 1.31,
... |
ANODE_SYNTH_2025_406 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 82,
"sex": "male",
"bmi": 19.5,
"smoking_pack_years": 52,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.5,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-08-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -72
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 7.3,
"censored": false
} | [
{
"date": "2025-06-23T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 10.3,
"platelets_k_uL": 272,
"creatinine_mg_dL": 0.76,
"alt_U_L": 29
},
{
"date": "2026-02-03T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 8.2,
"platelets_k_uL": 166,
"creatinine_mg_dL": 0.82,
... |
ANODE_SYNTH_2025_407 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 49,
"sex": "male",
"bmi": 30.8,
"smoking_pack_years": 14,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.4,
"metastatic_sites": [
"brain",
"pleura",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-03-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -71
},
"pfs_months": 13.08
},
"second_line_... | {
"overall_survival_months": 24,
"censored": false
} | [
{
"date": "2022-02-16T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 5.8,
"platelets_k_uL": 224,
"creatinine_mg_dL": 0.61,
"alt_U_L": 11
},
{
"date": "2022-09-20T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 6.4,
"platelets_k_uL": 127,
"creatinine_mg_dL": 0.84,
... |
ANODE_SYNTH_2025_408 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 73,
"sex": "female",
"bmi": 27,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-07-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 12.68
},
"second_line... | {
"overall_survival_months": 30,
"censored": false
} | [
{
"date": "2021-06-17T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 10.2,
"platelets_k_uL": 206,
"creatinine_mg_dL": 0.87,
"alt_U_L": 34
},
{
"date": "2022-01-10T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 7.9,
"platelets_k_uL": 136,
"creatinine_mg_dL": 0.73,
... |
ANODE_SYNTH_2025_409 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 70,
"sex": "female",
"bmi": 21.5,
"smoking_pack_years": 56,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-10-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 24.54
... | {
"overall_survival_months": 40.7,
"censored": true
} | [
{
"date": "2024-09-10T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 10,
"platelets_k_uL": 175,
"creatinine_mg_dL": 0.88,
"alt_U_L": 73
},
{
"date": "2025-04-29T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 4.2,
"platelets_k_uL": 267,
"creatinine_mg_dL": 1.49,
... |
ANODE_SYNTH_2025_410 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 75,
"sex": "female",
"bmi": 35.9,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7.9,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-01-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 18.4
},
"second_line_... | {
"overall_survival_months": 33.3,
"censored": true
} | [
{
"date": "2022-12-20T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 7.6,
"platelets_k_uL": 360,
"creatinine_mg_dL": 1.13,
"alt_U_L": 43
},
{
"date": "2023-07-17T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 5.1,
"platelets_k_uL": 223,
"creatinine_mg_dL": 1.56,
... |
ANODE_SYNTH_2025_411 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 77,
"sex": "female",
"bmi": 30.9,
"smoking_pack_years": 32,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.9,
"metastatic_sites": [
"liver",
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-12-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 10.84
},
"second_line_... | {
"overall_survival_months": 21.4,
"censored": false
} | [
{
"date": "2021-11-02T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 10.8,
"platelets_k_uL": 155,
"creatinine_mg_dL": 1.04,
"alt_U_L": 48
},
{
"date": "2022-06-03T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 7.8,
"platelets_k_uL": 191,
"creatinine_mg_dL": 1.5,
"... |
ANODE_SYNTH_2025_412 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 60,
"sex": "female",
"bmi": 35.3,
"smoking_pack_years": 18,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"brain",
"pleura",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-04-20T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -40
},
"pfs_months": 33.87
},
"second_line_ther... | {
"overall_survival_months": 53,
"censored": false
} | [
{
"date": "2025-03-16T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 10.6,
"platelets_k_uL": 423,
"creatinine_mg_dL": 1.2,
"alt_U_L": 78
},
{
"date": "2025-10-17T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 8.8,
"platelets_k_uL": 221,
"creatinine_mg_dL": 0.75,
"... |
ANODE_SYNTH_2025_413 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 12
} | {
"age": 60,
"sex": "female",
"bmi": 26.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-07-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -53
},
"pfs_months": 24.67
},
"second_line... | {
"overall_survival_months": 35.6,
"censored": false
} | [
{
"date": "2024-06-24T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 8.7,
"platelets_k_uL": 274,
"creatinine_mg_dL": 0.67,
"alt_U_L": 15
},
{
"date": "2025-01-14T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 4.8,
"platelets_k_uL": 375,
"creatinine_mg_dL": 0.75,
... |
ANODE_SYNTH_2025_414 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 65,
"sex": "female",
"bmi": 29.6,
"smoking_pack_years": 45,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6,
"metastatic_sites": [
"brain",
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-04-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -67
},
"pfs_months": 33.35
},
"second_line_th... | {
"overall_survival_months": 48.8,
"censored": true
} | [
{
"date": "2023-03-10T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 9.1,
"platelets_k_uL": 414,
"creatinine_mg_dL": 0.63,
"alt_U_L": 72
},
{
"date": "2023-10-03T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 6.3,
"platelets_k_uL": 300,
"creatinine_mg_dL": 1.26,
"... |
ANODE_SYNTH_2025_415 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 87,
"sex": "female",
"bmi": 29.3,
"smoking_pack_years": 23,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-08-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -69
},
"pfs_months": 3.52
},
"second_line_t... | {
"overall_survival_months": 12.2,
"censored": true
} | [
{
"date": "2022-07-14T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 9.3,
"platelets_k_uL": 347,
"creatinine_mg_dL": 0.71,
"alt_U_L": 55
},
{
"date": "2023-02-24T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 6.9,
"platelets_k_uL": 313,
"creatinine_mg_dL": 1.02,
... |
ANODE_SYNTH_2025_416 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2
} | {
"age": 48,
"sex": "female",
"bmi": 32.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-05-04T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -75
},
"pfs_months": 15.31
},
"second_line_t... | {
"overall_survival_months": 34.6,
"censored": false
} | [
{
"date": "2021-03-04T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 6.5,
"platelets_k_uL": 239,
"creatinine_mg_dL": 0.77,
"alt_U_L": 70
},
{
"date": "2021-10-31T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 8.9,
"platelets_k_uL": 356,
"creatinine_mg_dL": 0.93,
"... |
ANODE_SYNTH_2025_417 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 73,
"sex": "female",
"bmi": 21.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-03-11T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 24.31
},
"second_line_t... | {
"overall_survival_months": 41.6,
"censored": true
} | [
{
"date": "2021-01-12T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 6.7,
"platelets_k_uL": 199,
"creatinine_mg_dL": 0.98,
"alt_U_L": 40
},
{
"date": "2021-09-07T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 5.6,
"platelets_k_uL": 311,
"creatinine_mg_dL": 1.02,
... |
ANODE_SYNTH_2025_418 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 88,
"sex": "female",
"bmi": 25.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-02-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 22.18
},
"second_line... | {
"overall_survival_months": 37.8,
"censored": false
} | [
{
"date": "2020-01-07T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 5.2,
"platelets_k_uL": 314,
"creatinine_mg_dL": 1.1,
"alt_U_L": 42
},
{
"date": "2020-07-30T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 6.5,
"platelets_k_uL": 149,
"creatinine_mg_dL": 0.8,
"... |
ANODE_SYNTH_2025_419 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2
} | {
"age": 74,
"sex": "female",
"bmi": 32.9,
"smoking_pack_years": 47,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2021-03-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -23,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 33.54
},
"second_line_th... | {
"overall_survival_months": 61.7,
"censored": false
} | [
{
"date": "2021-01-06T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 9.5,
"platelets_k_uL": 378,
"creatinine_mg_dL": 0.8,
"alt_U_L": 73
},
{
"date": "2021-08-29T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 5.9,
"platelets_k_uL": 269,
"creatinine_mg_dL": 0.75,
... |
ANODE_SYNTH_2025_420 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 26
} | {
"age": 85,
"sex": "female",
"bmi": 35.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-06-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -42
},
"pfs_months": 17.25
},
"second_line... | {
"overall_survival_months": 37.8,
"censored": true
} | [
{
"date": "2023-05-18T00:00:00",
"hemoglobin_g_dL": 15.4,
"wbc_k_uL": 10.2,
"platelets_k_uL": 282,
"creatinine_mg_dL": 1.08,
"alt_U_L": 10
},
{
"date": "2023-11-29T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 5.3,
"platelets_k_uL": 159,
"creatinine_mg_dL": 1.06,
... |
ANODE_SYNTH_2025_421 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 76,
"sex": "male",
"bmi": 24.1,
"smoking_pack_years": 65,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"pleura",
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-02-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 19.61
},
"second_line_... | {
"overall_survival_months": 23.6,
"censored": true
} | [
{
"date": "2020-01-23T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 8.3,
"platelets_k_uL": 446,
"creatinine_mg_dL": 1.24,
"alt_U_L": 54
},
{
"date": "2020-08-23T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 4.1,
"platelets_k_uL": 326,
"creatinine_mg_dL": 1.16,
... |
ANODE_SYNTH_2025_422 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 86,
"sex": "female",
"bmi": 18.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.4,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-10-17T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 6.97
},
"second_line_th... | {
"overall_survival_months": 21.4,
"censored": false
} | [
{
"date": "2022-08-27T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 9.7,
"platelets_k_uL": 165,
"creatinine_mg_dL": 1.24,
"alt_U_L": 53
},
{
"date": "2023-04-15T00:00:00",
"hemoglobin_g_dL": 10.1,
"wbc_k_uL": 5.9,
"platelets_k_uL": 256,
"creatinine_mg_dL": 1.3,
... |
ANODE_SYNTH_2025_423 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 52,
"sex": "female",
"bmi": 29.2,
"smoking_pack_years": 13,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.6,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-07-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -49
},
"pfs_months": 26.41
... | {
"overall_survival_months": 36.1,
"censored": false
} | [
{
"date": "2022-05-02T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 10.3,
"platelets_k_uL": 184,
"creatinine_mg_dL": 1.18,
"alt_U_L": 34
},
{
"date": "2023-01-04T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 6.5,
"platelets_k_uL": 232,
"creatinine_mg_dL": 1.23,
... |
ANODE_SYNTH_2025_424 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 85,
"sex": "female",
"bmi": 36.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"pleura",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-04-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -38,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 23.49
},
"second_line... | {
"overall_survival_months": 39.1,
"censored": false
} | [
{
"date": "2022-02-11T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 8.6,
"platelets_k_uL": 156,
"creatinine_mg_dL": 0.85,
"alt_U_L": 18
},
{
"date": "2022-10-11T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 4.5,
"platelets_k_uL": 184,
"creatinine_mg_dL": 1.27,
... |
ANODE_SYNTH_2025_425 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 59,
"sex": "male",
"bmi": 29.1,
"smoking_pack_years": 66,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.8,
"metastatic_sites": [
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-08-18T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 18.04
},... | {
"overall_survival_months": 38.7,
"censored": true
} | [
{
"date": "2022-08-04T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 8.2,
"platelets_k_uL": 448,
"creatinine_mg_dL": 1.25,
"alt_U_L": 40
},
{
"date": "2023-02-14T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 8.5,
"platelets_k_uL": 146,
"creatinine_mg_dL": 1.21,
... |
ANODE_SYNTH_2025_426 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 76,
"sex": "male",
"bmi": 29.8,
"smoking_pack_years": 48,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-02-11T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 20.11
},... | {
"overall_survival_months": 35.2,
"censored": false
} | [
{
"date": "2024-12-18T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 4.7,
"platelets_k_uL": 239,
"creatinine_mg_dL": 1,
"alt_U_L": 54
},
{
"date": "2025-08-10T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 4.6,
"platelets_k_uL": 309,
"creatinine_mg_dL": 1.26,
"a... |
ANODE_SYNTH_2025_427 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 81,
"sex": "female",
"bmi": 24.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.9,
"metastatic_sites": [
"pleura",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-03-09T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 17.77
},
"second_line... | {
"overall_survival_months": 35.7,
"censored": false
} | [
{
"date": "2020-01-16T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 10.7,
"platelets_k_uL": 385,
"creatinine_mg_dL": 0.75,
"alt_U_L": 12
},
{
"date": "2020-09-05T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 5.4,
"platelets_k_uL": 143,
"creatinine_mg_dL": 1.09,
... |
ANODE_SYNTH_2025_428 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 84,
"sex": "female",
"bmi": 31.7,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.9,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-07-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -39,
"peak_response_20wk_change_percent": -40
},
"pfs_months": 22.9
},
"second_line_... | {
"overall_survival_months": 36.6,
"censored": false
} | [
{
"date": "2020-06-06T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 6.3,
"platelets_k_uL": 191,
"creatinine_mg_dL": 0.74,
"alt_U_L": 36
},
{
"date": "2021-01-19T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 5.2,
"platelets_k_uL": 181,
"creatinine_mg_dL": 1.29,
... |
ANODE_SYNTH_2025_429 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 80,
"sex": "female",
"bmi": 21.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"bone",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-02-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -53
},
"pfs_months": 18.86
},
"second_line... | {
"overall_survival_months": 38.5,
"censored": false
} | [
{
"date": "2023-01-18T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 10.4,
"platelets_k_uL": 426,
"creatinine_mg_dL": 0.98,
"alt_U_L": 22
},
{
"date": "2023-08-11T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 4.5,
"platelets_k_uL": 319,
"creatinine_mg_dL": 0.73,
... |
ANODE_SYNTH_2025_430 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 48,
"sex": "female",
"bmi": 35.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"contralateral lung",
"brain",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-09-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -35
},
"pfs_months": 27.63
},
"second_line... | {
"overall_survival_months": 42.2,
"censored": false
} | [
{
"date": "2020-08-26T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 6.5,
"platelets_k_uL": 395,
"creatinine_mg_dL": 1.28,
"alt_U_L": 73
},
{
"date": "2021-03-27T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 7.4,
"platelets_k_uL": 244,
"creatinine_mg_dL": 1.1,
"a... |
ANODE_SYNTH_2025_431 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 49,
"sex": "female",
"bmi": 23.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.5,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-10-11T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -23,
"peak_response_20wk_change_percent": -69
},
"pfs_months": 15.87
},
"second_line... | {
"overall_survival_months": 28.1,
"censored": true
} | [
{
"date": "2020-09-13T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 7.2,
"platelets_k_uL": 438,
"creatinine_mg_dL": 0.99,
"alt_U_L": 25
},
{
"date": "2021-04-09T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 7.3,
"platelets_k_uL": 219,
"creatinine_mg_dL": 1.13,
... |
ANODE_SYNTH_2025_432 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 72,
"sex": "female",
"bmi": 30.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-06-09T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -14,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 17.84
},
"second_line... | {
"overall_survival_months": 30.7,
"censored": false
} | [
{
"date": "2020-05-21T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 7.5,
"platelets_k_uL": 360,
"creatinine_mg_dL": 0.73,
"alt_U_L": 26
},
{
"date": "2020-12-06T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 8.3,
"platelets_k_uL": 204,
"creatinine_mg_dL": 1.56,
... |
ANODE_SYNTH_2025_433 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 68,
"sex": "male",
"bmi": 37.5,
"smoking_pack_years": 61,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"brain",
"contralateral lung",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-06-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -34
},
"pfs_months": 24.61
... | {
"overall_survival_months": 34.1,
"censored": false
} | [
{
"date": "2021-04-03T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 9.2,
"platelets_k_uL": 316,
"creatinine_mg_dL": 0.83,
"alt_U_L": 10
},
{
"date": "2021-11-28T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 7.2,
"platelets_k_uL": 280,
"creatinine_mg_dL": 1.57,
"... |
ANODE_SYNTH_2025_434 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 57,
"sex": "male",
"bmi": 24,
"smoking_pack_years": 25,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-10-25T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -30
},
"pfs_months": 16.66
},
"second_line_th... | {
"overall_survival_months": 20.6,
"censored": false
} | [
{
"date": "2025-08-19T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 4.9,
"platelets_k_uL": 242,
"creatinine_mg_dL": 0.92,
"alt_U_L": 53
},
{
"date": "2026-04-23T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 7.1,
"platelets_k_uL": 373,
"creatinine_mg_dL": 1.44,
... |
ANODE_SYNTH_2025_435 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 25
} | {
"age": 73,
"sex": "female",
"bmi": 22.1,
"smoking_pack_years": 80,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 7.2,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-06-12T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 9.59
},
"second_line_the... | {
"overall_survival_months": 23.8,
"censored": true
} | [
{
"date": "2022-05-21T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 7.9,
"platelets_k_uL": 292,
"creatinine_mg_dL": 0.82,
"alt_U_L": 58
},
{
"date": "2022-12-09T00:00:00",
"hemoglobin_g_dL": 10.4,
"wbc_k_uL": 3.9,
"platelets_k_uL": 304,
"creatinine_mg_dL": 1.04,
... |
ANODE_SYNTH_2025_436 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "NTRK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 83,
"sex": "female",
"bmi": 20.4,
"smoking_pack_years": 70,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 7.2,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "larotrectinib 100 mg BID",
"start_date": "2025-06-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -36,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 2.96
},
"second_line... | {
"overall_survival_months": 15.6,
"censored": false
} | [
{
"date": "2025-04-16T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 9.5,
"platelets_k_uL": 448,
"creatinine_mg_dL": 0.97,
"alt_U_L": 72
},
{
"date": "2025-12-11T00:00:00",
"hemoglobin_g_dL": 11.3,
"wbc_k_uL": 4.5,
"platelets_k_uL": 184,
"creatinine_mg_dL": 1.26,
... |
ANODE_SYNTH_2025_437 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28
} | {
"age": 88,
"sex": "male",
"bmi": 30.1,
"smoking_pack_years": 59,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-09-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 17.58
... | {
"overall_survival_months": 38.3,
"censored": false
} | [
{
"date": "2022-07-21T00:00:00",
"hemoglobin_g_dL": 15.4,
"wbc_k_uL": 6,
"platelets_k_uL": 319,
"creatinine_mg_dL": 0.99,
"alt_U_L": 36
},
{
"date": "2023-03-04T00:00:00",
"hemoglobin_g_dL": 10.5,
"wbc_k_uL": 7.9,
"platelets_k_uL": 333,
"creatinine_mg_dL": 1.25,
"... |
ANODE_SYNTH_2025_438 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 11
} | {
"age": 51,
"sex": "female",
"bmi": 19.2,
"smoking_pack_years": 16,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-11-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 23.82
... | {
"overall_survival_months": 49.3,
"censored": false
} | [
{
"date": "2025-09-11T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 6.4,
"platelets_k_uL": 190,
"creatinine_mg_dL": 0.85,
"alt_U_L": 14
},
{
"date": "2026-05-18T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 7.4,
"platelets_k_uL": 365,
"creatinine_mg_dL": 1.13,
... |
ANODE_SYNTH_2025_439 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 52,
"sex": "female",
"bmi": 19.6,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"contralateral lung",
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-07-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -40,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 14.29
},
"second_line... | {
"overall_survival_months": 33,
"censored": true
} | [
{
"date": "2021-05-02T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 9,
"platelets_k_uL": 416,
"creatinine_mg_dL": 0.8,
"alt_U_L": 80
},
{
"date": "2022-01-03T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 6,
"platelets_k_uL": 281,
"creatinine_mg_dL": 1.06,
"alt... |
ANODE_SYNTH_2025_440 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 13,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 48,
"sex": "female",
"bmi": 23.6,
"smoking_pack_years": 59,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.2,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-08-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -35
},
"pfs_months": 18.79
},
"second_line_... | {
"overall_survival_months": 22.7,
"censored": false
} | [
{
"date": "2025-08-10T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 7.8,
"platelets_k_uL": 241,
"creatinine_mg_dL": 0.76,
"alt_U_L": 16
},
{
"date": "2026-02-23T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 5.9,
"platelets_k_uL": 237,
"creatinine_mg_dL": 1.1,
... |
ANODE_SYNTH_2025_441 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2
} | {
"age": 65,
"sex": "male",
"bmi": 29.7,
"smoking_pack_years": 65,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"contralateral lung",
"bone",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-02-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 18.27
... | {
"overall_survival_months": 28.4,
"censored": false
} | [
{
"date": "2024-01-14T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 8.4,
"platelets_k_uL": 438,
"creatinine_mg_dL": 1.19,
"alt_U_L": 66
},
{
"date": "2024-08-22T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 4.1,
"platelets_k_uL": 338,
"creatinine_mg_dL": 0.71,
... |
ANODE_SYNTH_2025_442 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 84,
"sex": "male",
"bmi": 25.7,
"smoking_pack_years": 56,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.1,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-11-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -27,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 9.33
},
"second_line_t... | {
"overall_survival_months": 13.3,
"censored": true
} | [
{
"date": "2023-10-02T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 7,
"platelets_k_uL": 410,
"creatinine_mg_dL": 0.69,
"alt_U_L": 55
},
{
"date": "2024-05-20T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4.1,
"platelets_k_uL": 350,
"creatinine_mg_dL": 1.14,
"... |
ANODE_SYNTH_2025_443 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 69,
"sex": "female",
"bmi": 18.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 8,
"metastatic_sites": [
"brain",
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-05-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -57,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 18.04
},
"second_line... | {
"overall_survival_months": 34.7,
"censored": true
} | [
{
"date": "2023-04-06T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 5,
"platelets_k_uL": 256,
"creatinine_mg_dL": 1.23,
"alt_U_L": 80
},
{
"date": "2023-11-20T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 4.9,
"platelets_k_uL": 338,
"creatinine_mg_dL": 1.07,
"... |
ANODE_SYNTH_2025_444 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 55,
"sex": "female",
"bmi": 21.9,
"smoking_pack_years": 79,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-08-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -55
},
"pfs_months": 22.83
... | {
"overall_survival_months": 31.4,
"censored": false
} | [
{
"date": "2022-07-25T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 7.9,
"platelets_k_uL": 229,
"creatinine_mg_dL": 0.61,
"alt_U_L": 20
},
{
"date": "2023-02-27T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 6.8,
"platelets_k_uL": 270,
"creatinine_mg_dL": 1.25,
"... |
ANODE_SYNTH_2025_445 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 74,
"sex": "female",
"bmi": 25.8,
"smoking_pack_years": 17,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.5,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-06-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -64
},
"pfs_months": 51.35
},
"second_line_th... | {
"overall_survival_months": 71.5,
"censored": true
} | [
{
"date": "2022-05-06T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 6.9,
"platelets_k_uL": 344,
"creatinine_mg_dL": 0.81,
"alt_U_L": 45
},
{
"date": "2022-12-25T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 5,
"platelets_k_uL": 351,
"creatinine_mg_dL": 1.57,
"... |
ANODE_SYNTH_2025_446 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 75,
"sex": "male",
"bmi": 19.9,
"smoking_pack_years": 65,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.2,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-11-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -13,
"peak_response_20wk_change_percent": -82
},
"pfs_months": 9.3
},
"second_line_th... | {
"overall_survival_months": 13.6,
"censored": true
} | [
{
"date": "2020-09-14T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 9,
"platelets_k_uL": 266,
"creatinine_mg_dL": 0.77,
"alt_U_L": 30
},
{
"date": "2021-05-07T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 6.4,
"platelets_k_uL": 218,
"creatinine_mg_dL": 1.32,
"... |
ANODE_SYNTH_2025_447 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 85,
"sex": "female",
"bmi": 26.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.8,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-09-27T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -19,
"peak_response_20wk_change_percent": -41
},
"pfs_months": 20.99
},
"second_line_t... | {
"overall_survival_months": 32.9,
"censored": false
} | [
{
"date": "2021-07-19T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 10.5,
"platelets_k_uL": 264,
"creatinine_mg_dL": 1.12,
"alt_U_L": 12
},
{
"date": "2022-03-26T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 8.3,
"platelets_k_uL": 197,
"creatinine_mg_dL": 1.51,
... |
ANODE_SYNTH_2025_448 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 49,
"sex": "female",
"bmi": 20.6,
"smoking_pack_years": 34,
"ecog_performance_status": 0,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.5,
"metastatic_sites": [
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-02-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 25.03
... | {
"overall_survival_months": 41.3,
"censored": false
} | [
{
"date": "2021-01-24T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 8.5,
"platelets_k_uL": 355,
"creatinine_mg_dL": 0.75,
"alt_U_L": 17
},
{
"date": "2021-08-24T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 7.9,
"platelets_k_uL": 271,
"creatinine_mg_dL": 1.35,
... |
ANODE_SYNTH_2025_449 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 77,
"sex": "female",
"bmi": 34,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"bone",
"liver",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-09-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 22.01
},
"second_line... | {
"overall_survival_months": 35.5,
"censored": false
} | [
{
"date": "2022-08-04T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 9,
"platelets_k_uL": 377,
"creatinine_mg_dL": 1.29,
"alt_U_L": 19
},
{
"date": "2023-03-07T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 5.1,
"platelets_k_uL": 142,
"creatinine_mg_dL": 0.93,
"... |
ANODE_SYNTH_2025_450 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 71,
"sex": "female",
"bmi": 34.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3.5,
"metastatic_sites": [
"pleura",
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-04-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 32.23
},
"second_line... | {
"overall_survival_months": 47.1,
"censored": true
} | [
{
"date": "2021-03-11T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 9.1,
"platelets_k_uL": 368,
"creatinine_mg_dL": 0.9,
"alt_U_L": 52
},
{
"date": "2021-10-12T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.8,
"platelets_k_uL": 330,
"creatinine_mg_dL": 0.72,
... |
ANODE_SYNTH_2025_451 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 77,
"sex": "male",
"bmi": 30.2,
"smoking_pack_years": 60,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.9,
"metastatic_sites": [
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-11-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 11.47
},
"second_line_... | {
"overall_survival_months": 15.4,
"censored": false
} | [
{
"date": "2024-11-01T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 11,
"platelets_k_uL": 340,
"creatinine_mg_dL": 1.02,
"alt_U_L": 47
},
{
"date": "2025-05-15T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 8.7,
"platelets_k_uL": 276,
"creatinine_mg_dL": 0.82,
... |
ANODE_SYNTH_2025_452 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 60,
"sex": "male",
"bmi": 33.6,
"smoking_pack_years": 13,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-07-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -31,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 54.74
},
"second_line_th... | {
"overall_survival_months": 80.5,
"censored": false
} | [
{
"date": "2020-06-14T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 9.9,
"platelets_k_uL": 421,
"creatinine_mg_dL": 1.17,
"alt_U_L": 73
},
{
"date": "2021-01-19T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 3.8,
"platelets_k_uL": 235,
"creatinine_mg_dL": 1.1,
"a... |
ANODE_SYNTH_2025_453 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 26
} | {
"age": 54,
"sex": "male",
"bmi": 24.2,
"smoking_pack_years": 49,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.9,
"metastatic_sites": [
"pleura",
"bone",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2021-09-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 31.87
},
"second_line_th... | {
"overall_survival_months": 60.5,
"censored": true
} | [
{
"date": "2021-07-21T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 9.2,
"platelets_k_uL": 229,
"creatinine_mg_dL": 0.64,
"alt_U_L": 53
},
{
"date": "2022-03-07T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 6.4,
"platelets_k_uL": 220,
"creatinine_mg_dL": 1.19,
... |
ANODE_SYNTH_2025_454 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 50,
"sex": "female",
"bmi": 37,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-09-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -81
},
"pfs_months": 19.71
},
"second_line... | {
"overall_survival_months": 29.8,
"censored": true
} | [
{
"date": "2021-07-12T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 9.1,
"platelets_k_uL": 173,
"creatinine_mg_dL": 1.23,
"alt_U_L": 76
},
{
"date": "2022-03-16T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 8,
"platelets_k_uL": 284,
"creatinine_mg_dL": 1,
"alt... |
ANODE_SYNTH_2025_455 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 84,
"sex": "female",
"bmi": 33.9,
"smoking_pack_years": 43,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"brain",
"pleura",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-03-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -54
},
"pfs_months": 12.25
},
"second_line_... | {
"overall_survival_months": 17.5,
"censored": false
} | [
{
"date": "2020-01-27T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.3,
"platelets_k_uL": 222,
"creatinine_mg_dL": 1.22,
"alt_U_L": 12
},
{
"date": "2020-09-23T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 8.5,
"platelets_k_uL": 310,
"creatinine_mg_dL": 0.77,
... |
ANODE_SYNTH_2025_456 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 54,
"sex": "female",
"bmi": 19.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"brain",
"bone",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-07-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -69
},
"pfs_months": 7.03
},
"second_line_... | {
"overall_survival_months": 12.6,
"censored": true
} | [
{
"date": "2023-06-11T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 5.3,
"platelets_k_uL": 280,
"creatinine_mg_dL": 1.12,
"alt_U_L": 60
},
{
"date": "2024-01-01T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.1,
"platelets_k_uL": 316,
"creatinine_mg_dL": 1.27,
... |
ANODE_SYNTH_2025_457 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 83,
"sex": "male",
"bmi": 20.6,
"smoking_pack_years": 52,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-01-19T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 16.16
},
"second_line_th... | {
"overall_survival_months": 20.4,
"censored": false
} | [
{
"date": "2022-11-12T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 5.5,
"platelets_k_uL": 191,
"creatinine_mg_dL": 1.04,
"alt_U_L": 59
},
{
"date": "2023-07-18T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 5.4,
"platelets_k_uL": 144,
"creatinine_mg_dL": 0.94,
"al... |
ANODE_SYNTH_2025_458 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 74,
"sex": "male",
"bmi": 34.3,
"smoking_pack_years": 14,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-11-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 18.83
... | {
"overall_survival_months": 31.6,
"censored": false
} | [
{
"date": "2025-09-13T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 11,
"platelets_k_uL": 196,
"creatinine_mg_dL": 0.65,
"alt_U_L": 25
},
{
"date": "2026-05-01T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.6,
"platelets_k_uL": 304,
"creatinine_mg_dL": 1.27,
... |
ANODE_SYNTH_2025_459 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 62,
"sex": "male",
"bmi": 35.2,
"smoking_pack_years": 16,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.9,
"metastatic_sites": [
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-09-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 6.54
},
"second_line_t... | {
"overall_survival_months": 21.4,
"censored": false
} | [
{
"date": "2023-08-05T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 7.7,
"platelets_k_uL": 321,
"creatinine_mg_dL": 1.01,
"alt_U_L": 44
},
{
"date": "2024-03-20T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.4,
"platelets_k_uL": 356,
"creatinine_mg_dL": 1.15,
... |
ANODE_SYNTH_2025_460 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 83,
"sex": "female",
"bmi": 25.2,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2026-03-02T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 28.16
},
"second_line_t... | {
"overall_survival_months": 34.5,
"censored": false
} | [
{
"date": "2025-12-23T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 4.7,
"platelets_k_uL": 205,
"creatinine_mg_dL": 0.69,
"alt_U_L": 25
},
{
"date": "2026-08-29T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 6.8,
"platelets_k_uL": 148,
"creatinine_mg_dL": 1.28,
... |
ANODE_SYNTH_2025_461 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 75,
"sex": "male",
"bmi": 23.4,
"smoking_pack_years": 43,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 3,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-11-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 31.05
},
"second_line_th... | {
"overall_survival_months": 51.7,
"censored": false
} | [
{
"date": "2023-09-19T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 9.2,
"platelets_k_uL": 307,
"creatinine_mg_dL": 0.83,
"alt_U_L": 54
},
{
"date": "2024-05-20T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8.6,
"platelets_k_uL": 377,
"creatinine_mg_dL": 1.2,
... |
ANODE_SYNTH_2025_462 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 61,
"sex": "female",
"bmi": 34.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"pleura",
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-02-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 25.33
},
"second_line... | {
"overall_survival_months": 35.3,
"censored": false
} | [
{
"date": "2021-12-27T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 7.1,
"platelets_k_uL": 210,
"creatinine_mg_dL": 1.24,
"alt_U_L": 70
},
{
"date": "2022-08-22T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 7.8,
"platelets_k_uL": 355,
"creatinine_mg_dL": 1.41,
... |
ANODE_SYNTH_2025_463 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 55,
"sex": "female",
"bmi": 18.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 7.9,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-05-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 17.02
},
"second_line... | {
"overall_survival_months": 30.8,
"censored": false
} | [
{
"date": "2022-04-22T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 6.4,
"platelets_k_uL": 364,
"creatinine_mg_dL": 1.24,
"alt_U_L": 26
},
{
"date": "2022-11-26T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 5,
"platelets_k_uL": 271,
"creatinine_mg_dL": 1.44,
"al... |
ANODE_SYNTH_2025_464 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 48,
"sex": "male",
"bmi": 24.4,
"smoking_pack_years": 71,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-07-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 26.45
... | {
"overall_survival_months": 40.3,
"censored": false
} | [
{
"date": "2022-05-14T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 10.5,
"platelets_k_uL": 377,
"creatinine_mg_dL": 0.74,
"alt_U_L": 36
},
{
"date": "2023-01-09T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 6,
"platelets_k_uL": 331,
"creatinine_mg_dL": 0.86,
... |
ANODE_SYNTH_2025_465 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 63,
"sex": "male",
"bmi": 23.7,
"smoking_pack_years": 77,
"ecog_performance_status": 2,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.2,
"metastatic_sites": [
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-04-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -20,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 34.43
},
"second_line_th... | {
"overall_survival_months": 60.1,
"censored": false
} | [
{
"date": "2024-02-23T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 7.1,
"platelets_k_uL": 295,
"creatinine_mg_dL": 0.98,
"alt_U_L": 72
},
{
"date": "2024-10-14T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 7.7,
"platelets_k_uL": 137,
"creatinine_mg_dL": 1.3,
... |
ANODE_SYNTH_2025_466 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2
} | {
"age": 55,
"sex": "male",
"bmi": 34,
"smoking_pack_years": 76,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-09-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 39.49
},
"second_line_th... | {
"overall_survival_months": 62.2,
"censored": false
} | [
{
"date": "2022-08-17T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 10.6,
"platelets_k_uL": 377,
"creatinine_mg_dL": 0.92,
"alt_U_L": 69
},
{
"date": "2023-03-19T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 8.3,
"platelets_k_uL": 123,
"creatinine_mg_dL": 1.47,
... |
ANODE_SYNTH_2025_467 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 82,
"sex": "female",
"bmi": 36.6,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-04-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 26.61
},
"second_line... | {
"overall_survival_months": 31.9,
"censored": false
} | [
{
"date": "2020-02-09T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 9.5,
"platelets_k_uL": 215,
"creatinine_mg_dL": 1.13,
"alt_U_L": 28
},
{
"date": "2020-10-04T00:00:00",
"hemoglobin_g_dL": 10.2,
"wbc_k_uL": 7.7,
"platelets_k_uL": 275,
"creatinine_mg_dL": 1.31,
"... |
ANODE_SYNTH_2025_468 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 78,
"sex": "female",
"bmi": 20.3,
"smoking_pack_years": 30,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-11-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -18,
"peak_response_20wk_change_percent": -71
},
"pfs_months": 24.41
},
"second_line_... | {
"overall_survival_months": 31.4,
"censored": false
} | [
{
"date": "2023-09-13T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 7.4,
"platelets_k_uL": 153,
"creatinine_mg_dL": 0.75,
"alt_U_L": 61
},
{
"date": "2024-05-14T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 4.7,
"platelets_k_uL": 302,
"creatinine_mg_dL": 0.98,
... |
ANODE_SYNTH_2025_469 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 52,
"sex": "female",
"bmi": 28.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 8,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-07-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -30
},
"pfs_months": 20.83
},
"second_line... | {
"overall_survival_months": 31.8,
"censored": false
} | [
{
"date": "2020-05-24T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 7.8,
"platelets_k_uL": 422,
"creatinine_mg_dL": 0.94,
"alt_U_L": 34
},
{
"date": "2021-01-15T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 6.2,
"platelets_k_uL": 350,
"creatinine_mg_dL": 1.57,
... |
ANODE_SYNTH_2025_470 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 74,
"sex": "female",
"bmi": 18.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"bone",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-03-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -47
},
"pfs_months": 19.55
},
"second_line... | {
"overall_survival_months": 41.4,
"censored": false
} | [
{
"date": "2022-01-10T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 10.1,
"platelets_k_uL": 377,
"creatinine_mg_dL": 1.18,
"alt_U_L": 73
},
{
"date": "2022-09-01T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 4.6,
"platelets_k_uL": 340,
"creatinine_mg_dL": 0.78,
... |
ANODE_SYNTH_2025_471 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 72,
"sex": "female",
"bmi": 27,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3,
"metastatic_sites": [
"brain",
"bone",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-04-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -56,
"peak_response_20wk_change_percent": -47
},
"pfs_months": 38.51
},
"second_line... | {
"overall_survival_months": 50,
"censored": false
} | [
{
"date": "2022-03-04T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 8.9,
"platelets_k_uL": 221,
"creatinine_mg_dL": 0.61,
"alt_U_L": 26
},
{
"date": "2022-10-27T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 4.9,
"platelets_k_uL": 197,
"creatinine_mg_dL": 0.79,
"... |
ANODE_SYNTH_2025_472 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 80,
"sex": "female",
"bmi": 36.1,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"contralateral lung",
"bone",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-01-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 10.05
},
"second_line... | {
"overall_survival_months": 27.8,
"censored": false
} | [
{
"date": "2024-12-16T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 4.7,
"platelets_k_uL": 382,
"creatinine_mg_dL": 0.89,
"alt_U_L": 22
},
{
"date": "2025-07-15T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 4.8,
"platelets_k_uL": 296,
"creatinine_mg_dL": 0.72,
... |
ANODE_SYNTH_2025_473 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 50,
"sex": "female",
"bmi": 35.4,
"smoking_pack_years": 25,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.1,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-03-05T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 4.11
},
"second_line_the... | {
"overall_survival_months": 14.4,
"censored": false
} | [
{
"date": "2025-01-19T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 6.1,
"platelets_k_uL": 425,
"creatinine_mg_dL": 0.99,
"alt_U_L": 66
},
{
"date": "2025-09-01T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 5.1,
"platelets_k_uL": 320,
"creatinine_mg_dL": 0.87,
... |
ANODE_SYNTH_2025_474 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 62,
"sex": "female",
"bmi": 19,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-03-21T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -77
},
"pfs_months": 13.37
},
"second_line... | {
"overall_survival_months": 28.2,
"censored": false
} | [
{
"date": "2023-02-18T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 8.3,
"platelets_k_uL": 232,
"creatinine_mg_dL": 0.72,
"alt_U_L": 11
},
{
"date": "2023-09-17T00:00:00",
"hemoglobin_g_dL": 10.5,
"wbc_k_uL": 8.4,
"platelets_k_uL": 243,
"creatinine_mg_dL": 0.78,
"... |
ANODE_SYNTH_2025_475 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 70,
"sex": "female",
"bmi": 29.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"pleura",
"brain",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-09-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -51,
"peak_response_20wk_change_percent": -63
},
"pfs_months": 29.5
},
"second_line_... | {
"overall_survival_months": 46.4,
"censored": false
} | [
{
"date": "2023-09-01T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 6,
"platelets_k_uL": 437,
"creatinine_mg_dL": 1.19,
"alt_U_L": 39
},
{
"date": "2024-03-13T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 7.7,
"platelets_k_uL": 334,
"creatinine_mg_dL": 0.79,
"... |
ANODE_SYNTH_2025_476 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 11
} | {
"age": 77,
"sex": "female",
"bmi": 26.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 8,
"metastatic_sites": [
"brain",
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-03-06T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 19.02
},
"second_line_t... | {
"overall_survival_months": 28.5,
"censored": false
} | [
{
"date": "2020-01-19T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 7.7,
"platelets_k_uL": 151,
"creatinine_mg_dL": 0.96,
"alt_U_L": 77
},
{
"date": "2020-09-02T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 4.3,
"platelets_k_uL": 225,
"creatinine_mg_dL": 1.18,
... |
ANODE_SYNTH_2025_477 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 58,
"sex": "male",
"bmi": 37.7,
"smoking_pack_years": 65,
"ecog_performance_status": 0,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 8,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-05-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -19,
"peak_response_20wk_change_percent": -76
},
"pfs_months": 19.19
... | {
"overall_survival_months": 25.9,
"censored": false
} | [
{
"date": "2025-04-19T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 10.4,
"platelets_k_uL": 306,
"creatinine_mg_dL": 0.86,
"alt_U_L": 55
},
{
"date": "2025-11-22T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 5.3,
"platelets_k_uL": 288,
"creatinine_mg_dL": 0.81,
... |
ANODE_SYNTH_2025_478 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 62,
"sex": "female",
"bmi": 30.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.7,
"metastatic_sites": [
"contralateral lung",
"liver",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-01-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -64
},
"pfs_months": 23.62
},
"second_line... | {
"overall_survival_months": 37.7,
"censored": false
} | [
{
"date": "2021-12-23T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 10.2,
"platelets_k_uL": 298,
"creatinine_mg_dL": 1,
"alt_U_L": 72
},
{
"date": "2022-07-05T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 6,
"platelets_k_uL": 318,
"creatinine_mg_dL": 0.86,
"al... |
ANODE_SYNTH_2025_479 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 78,
"sex": "female",
"bmi": 31.9,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.9,
"metastatic_sites": [
"bone",
"brain",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-10-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 27.4
},
"second_line_... | {
"overall_survival_months": 43.4,
"censored": false
} | [
{
"date": "2024-08-22T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 10.1,
"platelets_k_uL": 325,
"creatinine_mg_dL": 0.67,
"alt_U_L": 55
},
{
"date": "2025-04-23T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 4.2,
"platelets_k_uL": 306,
"creatinine_mg_dL": 0.92,
... |
ANODE_SYNTH_2025_480 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 75,
"sex": "female",
"bmi": 29.1,
"smoking_pack_years": 69,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"pleura",
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-04-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 20.63
... | {
"overall_survival_months": 34.7,
"censored": false
} | [
{
"date": "2020-03-03T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 5.6,
"platelets_k_uL": 251,
"creatinine_mg_dL": 0.78,
"alt_U_L": 58
},
{
"date": "2020-10-17T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 5.2,
"platelets_k_uL": 264,
"creatinine_mg_dL": 1.28,
... |
ANODE_SYNTH_2025_481 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 51,
"sex": "female",
"bmi": 18.6,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.5,
"metastatic_sites": [
"bone",
"brain",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-11-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 10.25
},
"second_line... | {
"overall_survival_months": 20.5,
"censored": false
} | [
{
"date": "2020-09-28T00:00:00",
"hemoglobin_g_dL": 14.7,
"wbc_k_uL": 5.9,
"platelets_k_uL": 272,
"creatinine_mg_dL": 1.15,
"alt_U_L": 47
},
{
"date": "2021-05-11T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 6.8,
"platelets_k_uL": 345,
"creatinine_mg_dL": 1.49,
... |
ANODE_SYNTH_2025_482 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 54,
"sex": "female",
"bmi": 19.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"bone",
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-08-28T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -66
},
"pfs_months": 24.38
},
"second_line... | {
"overall_survival_months": 29.3,
"censored": true
} | [
{
"date": "2025-08-02T00:00:00",
"hemoglobin_g_dL": 15.4,
"wbc_k_uL": 8.8,
"platelets_k_uL": 335,
"creatinine_mg_dL": 1.28,
"alt_U_L": 15
},
{
"date": "2026-02-24T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 4.6,
"platelets_k_uL": 315,
"creatinine_mg_dL": 1.39,
... |
ANODE_SYNTH_2025_483 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 52,
"sex": "male",
"bmi": 33.3,
"smoking_pack_years": 54,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"liver",
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-01-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -60
},
"pfs_months": 21.91
... | {
"overall_survival_months": 37.5,
"censored": false
} | [
{
"date": "2020-11-17T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 7.8,
"platelets_k_uL": 373,
"creatinine_mg_dL": 1.28,
"alt_U_L": 21
},
{
"date": "2021-07-04T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 4.2,
"platelets_k_uL": 209,
"creatinine_mg_dL": 1.58,
... |
ANODE_SYNTH_2025_484 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 3.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 54,
"sex": "female",
"bmi": 28.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-09-09T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -40,
"peak_response_20wk_change_percent": -77
},
"pfs_months": 26.09
},
"second_line... | {
"overall_survival_months": 33.3,
"censored": true
} | [
{
"date": "2021-07-11T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 9,
"platelets_k_uL": 214,
"creatinine_mg_dL": 1.23,
"alt_U_L": 37
},
{
"date": "2022-03-08T00:00:00",
"hemoglobin_g_dL": 10.2,
"wbc_k_uL": 5.8,
"platelets_k_uL": 311,
"creatinine_mg_dL": 1.47,
"... |
ANODE_SYNTH_2025_485 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 82,
"sex": "female",
"bmi": 18.8,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-07-07T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 28.35
},
"second_line_t... | {
"overall_survival_months": 38.5,
"censored": false
} | [
{
"date": "2022-06-06T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 5.8,
"platelets_k_uL": 329,
"creatinine_mg_dL": 1.09,
"alt_U_L": 65
},
{
"date": "2023-01-03T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 4.3,
"platelets_k_uL": 158,
"creatinine_mg_dL": 1.46,
... |
ANODE_SYNTH_2025_486 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 55,
"sex": "male",
"bmi": 24.3,
"smoking_pack_years": 69,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"bone",
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-09-21T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -68
},
"pfs_months": 35.48
},
"second_line_ther... | {
"overall_survival_months": 54.4,
"censored": true
} | [
{
"date": "2024-08-18T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 6.9,
"platelets_k_uL": 252,
"creatinine_mg_dL": 0.85,
"alt_U_L": 39
},
{
"date": "2025-03-20T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 7.4,
"platelets_k_uL": 183,
"creatinine_mg_dL": 1.16,
... |
ANODE_SYNTH_2025_487 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 64,
"sex": "female",
"bmi": 20.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 7.3,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-05-26T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 21.36
},
"second_line_t... | {
"overall_survival_months": 42.8,
"censored": false
} | [
{
"date": "2022-04-02T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 5,
"platelets_k_uL": 349,
"creatinine_mg_dL": 1.06,
"alt_U_L": 41
},
{
"date": "2022-11-22T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 5,
"platelets_k_uL": 205,
"creatinine_mg_dL": 0.87,
"alt_... |
ANODE_SYNTH_2025_488 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 71,
"sex": "female",
"bmi": 23.4,
"smoking_pack_years": 11,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.3,
"metastatic_sites": [
"liver",
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-07-12T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -57,
"peak_response_20wk_change_percent": -64
},
"pfs_months": 16.07
},... | {
"overall_survival_months": 31.1,
"censored": false
} | [
{
"date": "2025-05-27T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 5.6,
"platelets_k_uL": 298,
"creatinine_mg_dL": 0.99,
"alt_U_L": 11
},
{
"date": "2026-01-08T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8.2,
"platelets_k_uL": 121,
"creatinine_mg_dL": 0.9,
... |
ANODE_SYNTH_2025_489 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 80,
"sex": "female",
"bmi": 23.6,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"brain",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-10-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 23.59
},
"second_line... | {
"overall_survival_months": 36.7,
"censored": false
} | [
{
"date": "2024-09-23T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 10.2,
"platelets_k_uL": 329,
"creatinine_mg_dL": 1.13,
"alt_U_L": 73
},
{
"date": "2025-04-22T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 4,
"platelets_k_uL": 348,
"creatinine_mg_dL": 1.23,
... |
ANODE_SYNTH_2025_490 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 71,
"sex": "female",
"bmi": 23.5,
"smoking_pack_years": 59,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-11-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -31,
"peak_response_20wk_change_percent": -38
},
"pfs_months": 46.39
},
"second_line_th... | {
"overall_survival_months": 68.3,
"censored": true
} | [
{
"date": "2020-09-13T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 10.6,
"platelets_k_uL": 229,
"creatinine_mg_dL": 1.22,
"alt_U_L": 58
},
{
"date": "2021-05-05T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.4,
"platelets_k_uL": 344,
"creatinine_mg_dL": 0.71,
... |
ANODE_SYNTH_2025_491 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 67,
"sex": "female",
"bmi": 18.9,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-10-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -39,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 19.45
},
"second_line... | {
"overall_survival_months": 27,
"censored": true
} | [
{
"date": "2023-08-22T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 7.6,
"platelets_k_uL": 384,
"creatinine_mg_dL": 0.8,
"alt_U_L": 28
},
{
"date": "2024-04-15T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.8,
"platelets_k_uL": 161,
"creatinine_mg_dL": 0.88,
... |
ANODE_SYNTH_2025_492 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 76,
"sex": "female",
"bmi": 28.1,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.4,
"metastatic_sites": [
"liver",
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-12-06T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 38.08
},
"second_line_t... | {
"overall_survival_months": 42,
"censored": false
} | [
{
"date": "2023-10-28T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 6.4,
"platelets_k_uL": 436,
"creatinine_mg_dL": 0.89,
"alt_U_L": 52
},
{
"date": "2024-06-03T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 5,
"platelets_k_uL": 155,
"creatinine_mg_dL": 1.13,
"... |
ANODE_SYNTH_2025_493 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 70,
"sex": "female",
"bmi": 19,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"contralateral lung",
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-08-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -36,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 16.13
},
"second_line... | {
"overall_survival_months": 25.6,
"censored": false
} | [
{
"date": "2024-06-18T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 10.9,
"platelets_k_uL": 381,
"creatinine_mg_dL": 0.88,
"alt_U_L": 35
},
{
"date": "2025-02-10T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 4,
"platelets_k_uL": 325,
"creatinine_mg_dL": 1.52,
... |
ANODE_SYNTH_2025_494 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 12
} | {
"age": 73,
"sex": "female",
"bmi": 24.6,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.5,
"metastatic_sites": [
"liver",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-04-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -44,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 18.79
},
"second_line... | {
"overall_survival_months": 23,
"censored": true
} | [
{
"date": "2025-03-08T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 6.3,
"platelets_k_uL": 206,
"creatinine_mg_dL": 0.82,
"alt_U_L": 23
},
{
"date": "2025-10-07T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 4.3,
"platelets_k_uL": 316,
"creatinine_mg_dL": 1.55,
... |
ANODE_SYNTH_2025_495 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 19
} | {
"age": 54,
"sex": "female",
"bmi": 37.1,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 7.2,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-05-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 32.46
},
"second_line... | {
"overall_survival_months": 45.5,
"censored": false
} | [
{
"date": "2022-03-25T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 8.8,
"platelets_k_uL": 169,
"creatinine_mg_dL": 0.98,
"alt_U_L": 61
},
{
"date": "2022-11-13T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 6,
"platelets_k_uL": 339,
"creatinine_mg_dL": 1.3,
"a... |
ANODE_SYNTH_2025_496 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 58,
"sex": "female",
"bmi": 25.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-02-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -60
},
"pfs_months": 23.16
},
"second_line... | {
"overall_survival_months": 34.6,
"censored": false
} | [
{
"date": "2021-01-04T00:00:00",
"hemoglobin_g_dL": 15.4,
"wbc_k_uL": 7.4,
"platelets_k_uL": 396,
"creatinine_mg_dL": 0.84,
"alt_U_L": 65
},
{
"date": "2021-08-07T00:00:00",
"hemoglobin_g_dL": 11.3,
"wbc_k_uL": 5.9,
"platelets_k_uL": 217,
"creatinine_mg_dL": 0.88,
... |
ANODE_SYNTH_2025_497 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 60,
"sex": "female",
"bmi": 25.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-03-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -40,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 25.92
},
"second_line... | {
"overall_survival_months": 42.2,
"censored": false
} | [
{
"date": "2020-01-18T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 7.3,
"platelets_k_uL": 163,
"creatinine_mg_dL": 1.11,
"alt_U_L": 13
},
{
"date": "2020-09-08T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 4.8,
"platelets_k_uL": 199,
"creatinine_mg_dL": 1.5,
... |
ANODE_SYNTH_2025_498 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 80,
"sex": "female",
"bmi": 25.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-07-15T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 27.33
},
"second_line... | {
"overall_survival_months": 45.9,
"censored": false
} | [
{
"date": "2020-05-14T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 9.8,
"platelets_k_uL": 221,
"creatinine_mg_dL": 0.87,
"alt_U_L": 45
},
{
"date": "2021-01-11T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 6.6,
"platelets_k_uL": 341,
"creatinine_mg_dL": 0.81,
... |
ANODE_SYNTH_2025_499 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24
} | {
"age": 49,
"sex": "female",
"bmi": 27.7,
"smoking_pack_years": 58,
"ecog_performance_status": 2,
"comorbidities": [
"COPD",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-06-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 17.74
... | {
"overall_survival_months": 37,
"censored": false
} | [
{
"date": "2024-05-23T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 9.6,
"platelets_k_uL": 343,
"creatinine_mg_dL": 0.68,
"alt_U_L": 40
},
{
"date": "2024-12-19T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 6.7,
"platelets_k_uL": 348,
"creatinine_mg_dL": 0.75,
... |
ANODE_SYNTH_2025_500 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 88,
"sex": "female",
"bmi": 24,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.5,
"metastatic_sites": [
"liver",
"brain",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-08-04T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 16.2
},
"second_line_th... | {
"overall_survival_months": 28,
"censored": true
} | [
{
"date": "2022-06-19T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 8.6,
"platelets_k_uL": 376,
"creatinine_mg_dL": 1.16,
"alt_U_L": 52
},
{
"date": "2023-01-31T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 7.7,
"platelets_k_uL": 215,
"creatinine_mg_dL": 0.8,
"a... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.